Monopar Therapeutics (NASDAQ:MNPR) Sets New 1-Year High - What's Next?

Key Points

• Monopar Therapeutics reached a new 52-week high of $120.42, with shares recently trading near $119.88 and up 4.1%; its market capitalization stood at approximately $831 million.
• Analyst sentiment is broadly positive, with an average “Buy” rating and a consensus price target of $112.08, although ratings range from “Strong Buy” to “Sell.” UBS set the highest cited target at $125, while BTIG raised its target to $117.
• The clinical-stage biotechnology company reported a quarterly loss of $0.46 per share, beating estimates for a $0.87 loss, but analysts expect a full-year loss of $2.82 per share. Institutional ownership remains limited at 1.83%, despite several large investors recently building positions.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) hit a new 52-week high on Thursday . The company traded as high as $120.42 and last traded at $119.8760, with a volume of 5572 shares changing hands. The stock had previously closed at $119.23.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MNPR. Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. BTIG Research upped their price objective on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Zacks Research upgraded shares of Monopar Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Monday, July 13th. Finally, Wall Street Zen downgraded shares of Monopar Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, July 12th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $112.08.

Monopar Therapeutics Trading Up 4.1%

The stock has a market capitalization of $831.08 million, a P/E ratio of -64.79 and a beta of 1.47. The company has a 50-day moving average price of $88.63 and a 200 day moving average price of $69.35.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.41. As a group, research analysts expect that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new stake in Monopar Therapeutics in the first quarter valued at approximately $673,000. Jane Street Group LLC acquired a new position in shares of Monopar Therapeutics during the first quarter worth $377,000. Geode Capital Management LLC increased its position in shares of Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock worth $3,468,000 after purchasing an additional 48,379 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at $209,000. Institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source